Novelos Therapeutics, Inc. and Medical University of South Carolina Abstract Accepted for Presentation at 2008 American Association for Cancer Research Annual Meeting

NEWTON, Mass.--(BUSINESS WIRE)--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos’ scientific abstract, based on the collaboration with Dr. Kenneth Tew and Dr. Danyelle Townsend of the Medical University of South Carolina (MUSC), has been accepted for a poster presentation at the American Association for Cancer Research (AACR) annual meeting in April 2008 in San Diego, CA, and will be published in the 2008 Proceedings of the AACR. This presentation will describe findings in cellular and animal model systems that demonstrate the ability of NOV-002 to influence redox balance in and around cells, resulting in a constellation of effects on redox-sensitive cell processes and functions. NOV-002 is the subject of an ongoing pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track, and is in Phase 2 trials for other oncology indications.
MORE ON THIS TOPIC